Bio-ReCell

From next-gen CAR-T therapy to brain-chip advancements, here are the latest breakthroughs making waves in biotech: 1. ALA-CART: Smarter CAR-T Therapy
 A novel CAR T cell design enhances antigen sensitivity, improving effectiveness in hard-to-treat cancers while reducing toxicity. Could this be the future of precision immunotherapy? Learn more: https://lnkd.in/e89aBBAg (Inside Precision Medicine) 2. Breast Cancer Treatment Faces a Hurdle
 Arvinas & Pfizer’s new protein-degrading drug showed strong results in a specific breast cancer mutation but struggled to stand out in broader trials. Is differentiation the biggest challenge in oncology drug development? Learn more: https://lnkd.in/emZFneRX (BioPharma Dive) 3. A Breakthrough for Rare Eye Disorders
 The FDA approved Neurotech’s first-ever treatment for MacTel Type 2, using an encapsulated cell therapy implant to slow disease progression. A new era for regenerative medicine? Learn more: https://lnkd.in/db7Ga9s8 (Fierce Pharma) 4. DNA Nanostructures for Drug Delivery
 Scientists have developed a way to assemble DNA nanostructures at body temperature, eliminating the need for extreme heat. This could revolutionize drug delivery and diagnostics. Learn more: https://lnkd.in/e_PpVVdt (Genetic Engineering & Biotechnology News) 5. Low-Power Brain Chip Predicts Intentions
 A new brain-computer interface monitors groups of neurons to detect when a user wants to move, using significantly less power. A step closer to seamless assistive tech for paralysis patients? Learn more: https://lnkd.in/ebSK3S2w (IEEE Spectrum) Biotech is evolving fast. What breakthrough excites you the most? Let’s us know below. #BioReCell #Biotech #Healthcare #Industry #Insights #News #Updates

We're #hiring a new Key Account Manager in Ljubljana, Ljubljana. Apply today or share this post with your network.

Our researcher Ozbej J. Popelar presented the company’s journey and his own career path at the second BioX industry meeting. He explained how Bio-ReCell’s technologies facilitate T-cell isolation, activation, and the purification of stromal vascular fraction or mesenchymal stem cells for use in autologous therapies. After the presentation, ASEF fellows participated in an insightful discussion, exploring the functionality of our innovative devices, the technology development process, and our promising future. Congratulations, Ožbej! #ASEF #BioReCell #BioX #Presentation #Education #CellTherapy #TCells #StemCells

Last week in biotech was packed with breakthroughs, from repurposing aspirin for cancer treatment to breakthrough gene therapies. Here’s what’s been happening: 1. Aspirin’s New Role in Cancer 
Researchers at the University of Cambridge discovered how aspirin helps the immune system stop cancer from spreading. By preventing platelets from shielding tumor cells, aspirin enables T-cells to attack metastasizing cancer. While promising, clinical trials are needed before it becomes a standard treatment. Learn more: https://lnkd.in/digicygX (BBC) 2. Next-Gen Immunotherapy: PD-1/VEGF Inhibitors vs. Keytruda 
A new class of bispecific cancer drugs targeting PD-1 and VEGF may outperform Merck’s blockbuster Keytruda. Ivonescimab, from Summit Therapeutics and Akeso, showed promising Phase 3 results in lung cancer, cutting the risk of progression by 50%. Could this be the next big leap in immunotherapy? Learn more: https://lnkd.in/eEkYNwJH (BioPharma Dive) 3. Targeting Brain Cancer Spread with TIMPs
 University of Nevada researchers are exploring how TIMPs (natural and engineered molecules) can block glioblastoma cells from spreading. By inhibiting MMP-9, these proteins could provide a much-needed new approach for treating aggressive brain tumors. Learn more: https://lnkd.in/enwrS7xj (Inside Precision Medicine) 4. Stem Cell Therapy Repairs Blinding Cornea Injuries 
An experimental stem cell treatment for limbal stem cell deficiency (LSCD) successfully restored cornea surfaces in 92% of patients in a clinical trial. The CALEC approach, developed at Mass Eye and Ear, offers new hope for people with previously untreatable vision loss. Learn more: https://lnkd.in/ehubwqZV (Genetic Engineering & Biotechnology News) 5. Battery-Powered MRI for Stroke Diagnosis 
Axana, a portable MRI scanner, could revolutionize stroke treatment by enabling early detection in emergency settings. Developed by Wellumio, this cost-effective, lightweight system runs on batteries and may soon be deployable in ambulances and rural hospitals. Learn more: https://lnkd.in/eWh-WngU (IEEE Spectrum) Which innovation excites you the most? Let us know in the comments below. #BioReCell #Biotech #Healthcare #Cancer #GeneTherapy #Breakthroughs #Industry #Insights

We're happy to announce our partnership with AcouSort AB. Together, we're developing a system for automated clean-up and isolation of stem cells and immune cells from adipose tissue. By combining AcouSort’s acoustofluidic expertise with our advanced digestion and isolation capabilities, we’re excited to further optimize our technology. Our initial trial at AcouSort’s facility in Lund successfully demonstrated the potential of acoustic separation on outputs from our Revive™ SVF isolation system. “Advancing technological excellence requires the synergy of compatible and forward-thinking partners. When these partners are industry leaders, success becomes even more attainable. Our collaboration with AcouSort exemplifies this principle, as we combine our expertise to drive innovation in cell therapy. Together, we are committed to revolutionizing the field by leveraging our joint competencies to push the boundaries of what’s possible.” – Luka Fajs, Ph.D., our CEO. #BioReCell #AcouSortAB #Partnership #Collaboration #SVF #StemCells #Cells

Struggling to stay informed about industry advancements with your busy schedule? We've collected last week's news just for you. 1. Tardigrade Protein Shields Cells from Radiation 
MIT researchers have developed a nanoparticle mRNA therapy using a tardigrade protein to protect healthy cells from radiation damage, offering potential for safer cancer treatments and even astronaut protection. Learn more: https://lnkd.in/e4v7DKA9 (Genetic Engineering & Biotechnology News) 2. Regeneron’s Gene Therapy Helps Deaf Children Hear 
In a groundbreaking trial, 10 out of 11 children born with congenital deafness showed hearing improvement after receiving Regeneron’s gene therapy, offering new hope for those with OTOF-related hearing loss. Learn more: https://lnkd.in/eW9r5R3Z (BioPharma Dive) 3. New Antibody-Toxin Conjugate Targets Cancer 
MD Anderson researchers have designed a new antibody-toxin conjugate (ATC) that trains the immune system to recognize and eliminate tumors, potentially providing a more durable cancer treatment approach. Learn more: https://lnkd.in/egritGYZ (Inside Precision Medicine) 4. Biopharma Revenue Surge Led by Eli Lilly & Novo Nordisk 
Lilly (45%) and Novo (30%) led a booming quarter for biopharma, driven by obesity and diabetes treatments, while Pfizer, AstraZeneca, and Astellas also saw double-digit growth. Learn more: https://lnkd.in/e2be8xdX (Fierce Pharma) 5. Eikon Therapeutics Secures $350M for Drug Development 
Eikon raised $350M to advance its clinical-stage programs, including cancer treatments powered by its cutting-edge protein-tracking technology. Learn more: https://lnkd.in/ep3SKXvD (Genetic Engineering & Biotechnology News) Which of these innovations do you think will have the biggest impact? Let’s discuss. #BioReCell #Biotech #Healthcare #Industry #Insights #News #Updates

Happy for contributing at my level to this amazing project !!.🤩👌..

Exciting news: Bio-ReCell is partnering with BIOTEM First Class Antibodies & Immunoassays. Through this strategic collaboration, we are integrating BIOTEM’s advanced humanized antibodies into our Atract™ T-cell activation kit and Neptune™ T-cell separation kit. This will enhance precision, efficiency, and scalability in cell therapy manufacturing to meet the industry’s growing demand for reliable solutions. Luka Fajs, Ph.D., our CEO, commented: “We deeply value our partnership with BIOTEM, as their humanized antibodies are essential to improving our cell activation and separation products. This collaboration helps us deliver high-performance solutions with consistent quality and reliability.” Read more: https://lnkd.in/eH7Nsggc #BioReCell #BIOTEM #Antibodies #CellSeparation #CellActivation #Partnership

Another week, another roundup of the latest in biotech. Catch up on what’s new: 1. Cancer Cells Cooperate to Fuel Tumor Growth 
NYU researchers found that cancer cells work together to extract nutrients, helping tumors survive in harsh conditions. Targeting this process with drugs like bestatin could open new treatment strategies. Learn more: https://lnkd.in/eQhtXwru (Inside Precision Medicine) 2. Solid’s Duchenne Gene Therapy Shows Strong Potential 
Early trial results suggest Solid Biosciences' SGT-003 gene therapy may be more potent than existing treatments, boosting muscle protein levels. The company is seeking FDA discussions for accelerated approval. Learn more: https://lnkd.in/eWsEqEey (BioPharma Dive) 3. FDA Expands Access to Bladder Cancer Drug BCG 
With BCG shortages limiting bladder cancer treatment, the FDA approved ImmunityBio and Serum Institute of India to supply an alternative, easing supply constraints until Merck expands production in 2026. Learn more: https://lnkd.in/ePzsgXJp (Fierce Pharma) 4. New Clue in Antibiotic Resistance 
Scientists discovered that gram-negative bacteria produce extra transporter proteins to pump out antibiotics. Targeting this mechanism could enhance existing treatments and slow resistance. Learn more: https://lnkd.in/ebwUbcJc (Genetic Engineering & Biotechnology News) 5. Progress Toward a Norovirus Vaccine 
With norovirus cases surging, researchers are developing vaccines, including Moderna’s mRNA approach. While challenges remain, a breakthrough may soon offer protection against this highly contagious virus. Learn more: https://lnkd.in/e3Fje8W4 (Scientific American) Which of these innovations intrigue you the most? Let’s us know. #BioReCell #Biotech #Healthcare #Industry #Insights #News #Updates

Another week, another roundup of the key happenings in biotech. Here’s what you need to know from the past week.
 1️. GLP-1 Drugs & Alcohol Cravings 
 A small clinical trial suggests semaglutide (Ozempic) may help reduce alcohol cravings and consumption, potentially extending its benefits beyond weight loss and diabetes management. However, larger trials are needed to confirm its effectiveness before regulatory approval. Learn more: https://lnkd.in/exzX-wxA (BioPharma Dive) 2️. Bristol Myers Expands Breyanzi’s Reach 
 Breyanzi, a CD19-directed CAR-T therapy, shows strong results in marginal zone lymphoma (MZL), an area with no approved CAR-T options. This marks its fifth successful indication as Bristol Myers intensifies competition with Gilead’s Yescarta and Tecartus. Learn more: https://lnkd.in/eAsj3YUY (Fierce Pharma) 3️. Genentech’s Gazyva Shines in Lupus Nephritis 
 Gazyva (obinutuzumab), a monoclonal antibody, demonstrated significant renal response in lupus nephritis patients. This breakthrough could offer a more accessible and effective alternative to CAR-T therapy for severe autoimmune diseases. Learn more: https://lnkd.in/eMNBHAec (Inside Precision Medicine) 4️. Diabetes & Antibiotic Resistance 
 New research reveals that diabetes accelerates the development of antibiotic-resistant Staphylococcus aureus infections. Controlling blood sugar levels with insulin was found to significantly slow the emergence of resistant bacterial strains, highlighting the link between metabolic health and infection control. Learn more: https://lnkd.in/eC5HEYUE (Genetic Engineering & Biotechnology News) 5️. AI Reads & Writes DNA 
 Evo, a groundbreaking genomic AI model, is capable of predicting genetic functions and designing synthetic DNA sequences. This technology could revolutionize biological engineering, accelerating discoveries in medicine, synthetic biology, and drug development. Learn more: https://lnkd.in/ezUs3UPB (Quanta Magazine) Which of these breakthroughs do you think will have the most lasting impact? Let us know in the comments. #biotech #lifesciences #AIinHealthcare #drugdiscovery #mRNA #biopharma